NasdaqGS:AMLXPharmaceuticals
Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap
Amylyx Pharmaceuticals (NasdaqGS:AMLX) is advancing avexitide through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH).
Pivotal Phase III data from LUCIDITY are expected next quarter.
The company has also started a U.S. expanded access program so certain PBH patients can receive avexitide before any potential approval.
Amylyx Pharmaceuticals focuses on therapies for serious neurological and metabolic conditions, with avexitide as its lead candidate for PBH. PBH can...